Mono Pharmacare Limited — Others, 08-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

Mono Pharmacare Limited has announced a board meeting to discuss the Statement of Deviation or Variation pursuant to SEBI regulations. They confirmed there has been no deviation in the utilization of funds from their initial public offering (IPO) amounting to ₹14.84 crore. As of March 31, 2024, the actual fund utilization totaled ₹13.57 crore, primarily for working capital and issue expenses, with ₹1.26 crore pending for future use. This clarity on fund management may contribute to a positive outlook among investors, reinforcing confidence in the firm's financial health and operational strategy.